Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN R WEBSTER

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1124129671
CMS profile
187421
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$344.12

25 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $344.12 25

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN R WEBSTER

NPI 1124129671 · CMS profile ID 187421

Allopathic & Osteopathic Physicians / Internal Medicine

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
BRIAN R WEBSTER, NPI 1124129671, CMS profile ID 187421, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–25 of 25 matching records. This page contains 25 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124129671?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

25 matching records · $344.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 25 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–25 of 25.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $14.0811/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720467485 CMS
Novo Nordisk Inc $5.7109/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744899649 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.7909/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720467489 CMS
Novo Nordisk Inc $25.0008/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744841789 CMS
Novo Nordisk Inc $12.0408/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744814309 CMS
IRONWOOD PHARMACEUTICALS, INC $11.8607/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 749817371 CMS
Novo Nordisk Inc $6.2106/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744757523 CMS
Novo Nordisk Inc $16.2305/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744693681 CMS
Kowa Pharmaceuticals America, Inc. $13.8503/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716723711 CMS
Lilly USA, LLC $13.8403/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728356859 CMS
SANOFI-AVENTIS U.S. LLC $11.5103/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744156151 CMS
Dynavax Technologies Corporation $18.1403/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747407237 CMS
Lilly USA, LLC $11.6002/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728356857 CMS
Amgen Inc. $12.9702/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740942163 CMS
Janssen Pharmaceuticals, Inc $11.5802/22/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719062941 CMS
Novo Nordisk Inc $17.3102/19/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744730465 CMS
Novo Nordisk Inc $14.2502/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744596247 CMS
BIODELIVERY SCIENCES INTERNATIONAL, INC. $13.0102/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747893453 CMS
GlaxoSmithKline, LLC. $12.5902/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738645835 CMS
Arbor Pharmaceuticals, Inc. $14.8502/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735747095 CMS
Amgen Inc. $14.6501/31/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740942161 CMS
Lilly USA, LLC $12.6501/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728370465 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $19.4201/15/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 720467493 CMS
Novo Nordisk Inc $12.9801/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744555867 CMS
PFIZER INC. $12.0001/02/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743661937 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,614.26 105
PY2020 $344.12 25
PY2021 $166.49 11
PY2022 $147.76 12
PY2023 $45.48 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,179,650.03 45
PY2024 Principal investigator $1,336,794.36 51
PY2023 Recipient $628.25 1
PY2023 Principal investigator $421,175.77 35
PY2022 Principal investigator $414,800.07 178
PY2021 Principal investigator $249,631.83 98
PY2020 Principal investigator $39,638.70 30
PY2019 Principal investigator $10,918.41 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Genentech, Inc. $1,186.25 11/27/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398356
Principal investigator 1 Eli Lilly and Company $22,010.00 11/22/2024 Non-covered Recipient Entity
INNOVO RESEARCH
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1137360829
Principal investigator 1 Genentech, Inc. $7,540.00 11/20/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398372
Principal investigator 1 Genentech, Inc. $22,549.00 11/20/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398392
Principal investigator 1 Genentech, Inc. $87,925.00 11/15/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398404
Principal investigator 1 Bausch Health US, LLC $3,850.00 11/04/2024 Non-covered Recipient Entity
Innovo Research Inc.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151669601
Principal investigator 1 Genentech, Inc. $18,433.00 10/30/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398350
Principal investigator 1 Eli Lilly and Company $219.00 10/28/2024 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
LONG-TERM REAL-WORLD COMPARATIVE EFFECTIVENESS OF DONANEMAB PLUS USUAL CARE VERSUS USUAL CARE ALONE IN US PATIENTS WITH EARLY SYMPTOMATIC ALZHEIMER'S DISEASE (TRAILBLAZER-REAL US) No dispute reported 06/30/2026 1137365975
Principal investigator 1 Genentech, Inc. $1,749.00 10/16/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398380
Principal investigator 1 Genentech, Inc. $41,940.00 10/16/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398412
Principal investigator 1 Genentech, Inc. $108,753.00 10/11/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398364
Principal investigator 1 Genentech, Inc. $8,498.00 10/02/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398342
Principal investigator 1 Genentech, Inc. $949.00 10/02/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398348
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,742.50 09/25/2024 Non-covered Recipient Entity
INNOVO RESEARCH LLC
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1110845931
Principal investigator 1 Genentech, Inc. $4,524.00 09/18/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398198
Principal investigator 1 Genentech, Inc. $4,836.00 09/18/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398290
Principal investigator 1 Eli Lilly and Company $26,260.00 09/11/2024 Non-covered Recipient Entity
INNOVO RESEARCH
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1137360443
Principal investigator 1 Genentech, Inc. $37,966.00 09/11/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398184
Principal investigator 1 Genentech, Inc. $18,433.00 08/28/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398264
Principal investigator 1 Genentech, Inc. $15,009.00 08/21/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398208
Principal investigator 1 GlaxoSmithKline, LLC. $6,461.30 08/21/2024 Non-covered Recipient Entity
INNOVO RESEARCH LLC
A PHASE III, RANDOMIZED, CONTROLLED, OBSERVER-BLIND STUDY TO EVALUATE No dispute reported 06/30/2026 1127522070
Principal investigator 1 Genentech, Inc. $42,348.00 08/07/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398166
Principal investigator 1 Genentech, Inc. $56,736.00 07/31/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398294
Principal investigator 1 Bausch Health US, LLC $450.00 07/15/2024 Non-covered Recipient Entity
Innovo Research Inc.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151669592
Principal investigator 1 Genentech, Inc. $28,439.00 07/12/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398298
Principal investigator 1 Genentech, Inc. $1,094.89 07/03/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398250
Principal investigator 1 Genentech, Inc. $61,260.00 07/03/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398282
Principal investigator 1 Genentech, Inc. $1,057.00 06/21/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398066
Principal investigator 1 Genentech, Inc. $3,495.00 06/21/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398070
Principal investigator 1 AstraZeneca Pharmaceuticals LP $77,061.16 06/14/2024 Non-covered Recipient Entity
INNOVO RESEARCH LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1110845839
Principal investigator 1 Genentech, Inc. $17,954.00 06/12/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398058
Principal investigator 1 Genentech, Inc. $34,329.00 05/31/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398096
Principal investigator 1 Genentech, Inc. $33,779.00 05/22/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398084
Principal investigator 1 Genentech, Inc. $11,922.00 05/01/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398076
Principal investigator 1 Genentech, Inc. $15,896.00 04/26/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398038
Principal investigator 1 Genentech, Inc. $89,415.00 04/24/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398056
Principal investigator 1 Genentech, Inc. $949.00 04/19/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398028
Principal investigator 1 Genentech, Inc. $15,896.00 04/12/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398046
Principal investigator 1 Bausch Health US, LLC $1,000.00 04/02/2024 Non-covered Recipient Entity
Innovo Research Inc.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151669481
Principal investigator 1 Bausch Health US, LLC $2,000.00 04/02/2024 Non-covered Recipient Entity
Innovo Research Inc.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151669490
Principal investigator 1 Bausch Health US, LLC $10,000.00 04/02/2024 Non-covered Recipient Entity
Innovo Research Inc.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151669522
Principal investigator 1 Bausch Health US, LLC $2,000.00 04/02/2024 Non-covered Recipient Entity
Innovo Research Inc.
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis No dispute reported 06/30/2026 1151669530
Principal investigator 1 Genentech, Inc. $9,935.00 03/29/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133398022
Principal investigator 1 Genentech, Inc. $53,649.00 03/20/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133397960
Principal investigator 1 Genentech, Inc. $711.75 03/15/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133397964
Principal investigator 1 Janssen Research & Development, LLC $12,720.00 01/26/2024 Non-covered Recipient Entity
Innovo Rsrch Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 1078961945
Principal investigator 1 Genentech, Inc. $268,245.00 01/24/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133397928
Principal investigator 1 Janssen Research & Development, LLC $5,597.00 01/12/2024 Non-covered Recipient Entity
Innovo Rsrch Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 1078961943
Principal investigator 1 Becton, Dickinson and Company $11,680.00 01/10/2024 Non-covered Recipient Entity
WILMINGTON ASC LLC
QuickSilver No dispute reported 06/30/2026 1130725590
Principal investigator 1 Eli Lilly and Company $4,393.51 01/08/2024 Non-covered Recipient Entity
WILMINGTON HEALTH
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1137370914
Principal investigator 1 Genentech, Inc. $949.00 01/05/2024 Non-covered Recipient Entity
INNOVO RESEARCH INC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133397952